In terms of partnership Wayne, the Sarepta / Roche deal is the...

First 47 Last

Share
Profile

Follow
Uboy

4,710 Posts.

1097

11/03/24

14:11

Post #: 72841599
Share

Originally posted by waynesworld ↑

The Phase IIb will complete enrolment towards the end of month. Then the clock starts ticking. Our instinct is to think about the data from the company point of view, not to mention the patients and their families and last but not least, the shareholders point of view. But what about from the point of view of the prospective partner who will fund a confirmatory trial in the event of accelerated approval or a Phase III trial.

That's all part of the positive data, positive signal and negative data conundrum. How would Big Pharma or Biggish Biotech balance the risk versus reward in terms of a commitment towards a partnership deal? To go early or go later, that is the question. The best case upside is huge: accelerated approval, Pediatric Priority Review Voucher, orphan drug designation and blockbuster market potential. To go early, means positioning for success but to go late could mean missing out all together. If the data points towards accelerated approval then not only does the price rise dramatically but it becomes a casino. Everyone wants a winning hand.

Putting on my Big Pharma cap I would definitely go early. Further, I would have been in regular contact with Percheron management over the last 12 months to win them over that my outfit is the best fit for a partnership. So, the clock is ticking and funnily enough time is running out for them to ink the partnership deal before Data Day.

Expand

In terms of partnership Wayne, the Sarepta / Roche deal is the closest we have to compare that is in our space - although i notice PER have taken that refence out of the company presentation.

Roche paid $1B up front to Sarepta for global rights outside of USA market (Gene Therapy).

Maybe GT carries a premium ...but so does inflammation control, which will allow Sarepta's and Pfizer's GT drugs to produce more dystrophin.

A partnership for US market, and PER keeping rest of world may be a good outcome.

It's reassuring to hear the CEO confirm that boys who have completed the first 6 months of trial, continuing on the program with either 25mg or 50mg dose.

.

.

PER Price at posting: 8.5¢ Sentiment: Buy Disclosure: Held
21 Upvote

2 Great analysis

Reply

Top Stories

NVU

Nanoveu surges 10% after benchmark testing for new AI chip begins

IRX

InhaleRX snags $38.5M in funding from VC biotech funder Clendon

SWP

Swoop lobs $18M offer at microcap telecom Vonex – in which it holds 19.9%

SNX

Sierra Nevada raises $2M for silver exploration at Blackhawk

What's causing the cost-of-living crisis, and how to navigate it

TLG

Talga Group wins key permit for flagship graphite mine in Sweden

M4M

Macro, Norden set up transport solutions initiative for West Pilbara

MTH

Mithril's drilling in Mexico picks up silver at 997g/t, gold at 28g/t

Week 42 Wrap: HotCopper's top picks; new ASX 200 record; world yawns at war

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint